Recently, Beijing Leadingpharm Medicine Technology Development Company (hereinafter referred to as "The Leadingpharm") successfully completed the financing of RMB 130 million, and the latest valuation exceeded RMB 1 billion!

Henan TALOPH company（Hereinafter referred to as TALOPH）held the seventh meeting of the eighth board of directors and the first extraordinary general meeting of shareholders in 2020 on May 26, 2020 and June 11, 2020, respectively, deliberated and passed the proposal on giving up the priority of capital increase and related party transactions of subsidiarie; It is agreed that the company and Henan Jinggang advanced manufacturing equity investment fund (limited partnership) (hereinafter referred to as "Jinggang fund") sign the capital increase agreement, Jinggang fund contributed RMB 130 million to Beijing Shenlanhai Biomedical Technology Co., Ltd. (hereinafter referred to as "shenlanhai") after its relocation to Zhengzhou, and obtained 20% of the equity, and then to increase capital to Beijing Leadingpharm Medicine Technology Development Company, and finally obtain 12.62% equity of The Leadingpharm based on the pre investment valuation of RMB 900 million; the above arrangement constitutes a package deal, and each step is interdependent or restricted to achieve the ultimate commercial purpose.
 

At present, Jinggang fund has completed all the capital contribution obligations to shenlanhai, and Shenlanhai has received capital increase of RMB 130 million from Jinggang fund. The completion of this transaction marks that the layout of the new leading CXO has been fully launched and will become the first real industry chain company with comprehensive solutions in the industry.